Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mim 8

Next Previous
X
Search
Drug Profile

Mim 8

Alternative Names: Coagulation factor VIII mimetic antibody - Novo Nordisk; FVIII mimetic antibody - Novo Nordisk; Mim-8; NN 7769; NN0365-3769; NNC0365-3769; NNC0365-3769 A

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Genmab; Novo Nordisk
  • Class Antihaemorrhagics; Bispecific antibodies
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 13 Nov 2024 Novo Nordisk completes a phase III trials in Haemophilia A (In children, In infants) in US, Netherlands, Canada, China, India, Israel, Italy, Japan, South Korea, Poland, Portugal, South Africa, Spain, Switzerland, Taiwan and United Kingdom (SC) (EudraCT2020-003467-26) (NCT05306418)
  • 07 Aug 2024 Novo Nordisk completes a phase-III trial in Haemophilia A (In adolescents, In the elderly, In adults) in Japan, USA, United Kingdom, Turkey, Switzerland, Spain, South Africa, Serbia, Saudi Arabia, Russia, Romania, Mexico, Malaysia, India, France, Czech Republic, China, Canada, Slovakia, Ireland, Denmark, Belgium, Germany, Austria, Latvia, Lithuania, Netherlands, Poland, Portugal, Italy, South Korea, Israel and Taiwan (SC) (NCT05053139)
  • 19 Jul 2024 Novo Nordisk completes a phase-III clinical trials in Haemophilia A (In adolescents, In adults, Treatment-experienced) in USA, Austria, Belgium, Canada, France, Germany, Italy, Japan, South Korea, South Africa, Spain, United Kingdom (SC) (NCT05878938)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top